IFPMA 2015 interview series ‘The threat of counterfeit medicines’
Ms Cyntia Genolet is IFPMA’s Policy Analyst, Regulatory & Health Policy and leads the organisation’s anti-counterfeiting portfolio. In this short interview, she gives a brief summary about the threat posed by counterfeit medicines and factors encouraging the trade of counterfeit medicines.
In 2015, IFPMA is organising two workshops on counterfeit medicines in Asia and Africa.
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. The industry’s two million employees discover, develop, and deliver medicines and vaccines that advance global health.
Learn more
Related news and resources
Fee system for regional joint assessment procedures in Africa
This joint position paper covers the perspective from industry on the proposed fee system for regional joint assessment procedures in Africa.
Read more
Pharmacy-mediated substitution for biosimilars
This position paper from IFPMA addresses substitution relating to biosimilars and their reference products at the retail pharmacy level. While this practice has been in place in many countries for generics, for biosimilars, the practice is only emerging.
Read more
Convergence and reliance approaches for advanced therapy medicinal products
Cell, tissue and gene therapies offer significant potential to treat diseases with high unmet medical needs, and consist of human cell and tissue products for medical use and advanced therapy medicinal products (ATMPs). IFPMA shares points to consider when promoting regulatory convergence and reliance approaches for ATMPs.
Read more